A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Phase 1 Completed 32 enrolled Boehringer Ingelheim

Non-randomizedCrossoverOpen-labelTreatment

Summary

For Part 1 of the trial, the main objective is to assess the effect of a single dose of zongertinib on the pharmacokinetics of a single dose of dabigatran-etexilate. For Part 2 of the trial, the main objective is to assess the effect of zongertinib at steady-state on the pharmacokinetics of a single dose of rosuvastatin, metformin and furosemide (administered as a cocktail).

Timeline

Start: 2024-08-20
Primary completion: 2024-10-03
Completion: 2024-12-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	150 mg	Oral
Subject	Furosemide	Other / unclassified	1 mg	Oral
Subject	Metformin	Small molecule	10 mg	Oral
Subject	Rosuvastatin	Small molecule	10 mg	Oral
Subject	Zongertinib	Small molecule	120 mg	Oral

Indications

No indication recorded.